Back to Search Start Over

MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression.

Authors :
Deng L
Liao L
Zhang YL
Hu SY
Yang SY
Ma XY
Huang MY
Zhang FL
Li DQ
Source :
Cancer letters [Cancer Lett] 2023 Apr 28; Vol. 560, pp. 216124. Date of Electronic Publication: 2023 Mar 11.
Publication Year :
2023

Abstract

Triple-negative breast cancer (TNBC), although highly lethal, lacks validated therapeutic targets. Here, we report that U2 snRNP-associated SURP motif-containing protein (U2SURP), a poorly defined member of the serine/arginine rich protein family, was significantly upregulated in TNBC tissues, and its high expression was associated with poor prognosis of TNBC patients. MYC, a frequently amplified oncogene in TNBC tissues, enhanced U2SURP translation through an eIF3D (eukaryotic translation initiation factor 3 subunit D)-dependent mechanism, resulting in the accumulation of U2SURP in TNBC tissues. Functional assays revealed that U2SURP played an important role in facilitating tumorigenesis and metastasis of TNBC cells both in vitro and in vivo. Intriguingly, U2SURP had no significant effects on proliferative, migratory, and invasive potential of normal mammary epithelial cells. Furthermore, we found that U2SURP promoted alternative splicing of spermidine/spermine N1-acetyltransferase 1 (SAT1) pre-mRNA by removal of intron 3, resulting in an increase in the stability of SAT1 mRNA and subsequent protein expression levels. Importantly, spliced SAT1 promoted the oncogenic properties of TNBC cells, and re-expression of SAT1 in U2SURP-depleted cells partially rescued the impaired malignant phenotypes of TNBC cells caused by U2SURP knockdown both in vitro and in mice. Collectively, these findings reveal previously unknown functional and mechanism roles of the MYC-U2SURP-SAT1 signaling axis in TNBC progression and highlight U2SURP as a potential therapy target for TNBC.<br />Competing Interests: Declaration of competing interest The authors declare no competing interests.<br /> (Copyright © 2023. Published by Elsevier B.V.)

Details

Language :
English
ISSN :
1872-7980
Volume :
560
Database :
MEDLINE
Journal :
Cancer letters
Publication Type :
Academic Journal
Accession number :
36907504
Full Text :
https://doi.org/10.1016/j.canlet.2023.216124